Evommune, Inc. EVMN shares jumped Tuesday following the announcement of positive top-line results from its Phase 2a trial evaluating EVO301 for treating moderate-to-severe atopic dermatitis. The ...
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...
InvestorsHub on MSN
Nektar gains after durable efficacy shown in atopic dermatitis study
Shares of Nektar Therapeutics (NASDAQ:NKTR) moved higher on Tuesday after the company released encouraging long-term maintenance results from its REZOLVE-AD trial of rezpegaldesleukin in patients with ...
Evommune (EVMN) stock surges as the company posts a mid-stage trial win for its experimental drug targeting atopic dermatitis ...
Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. Shares traded 13% higher ahead of the morning bell at $42.
Nektar Therapeutics (NKTR) stock jumps on positive mid-stage trial data for its experimental drug targeting atopic dermatitis. Read more here.
Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data ...
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadershipWill build ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results